Greenwich LifeSciences (NASDAQ:GLSI) added ~32% in the premarket on Wednesday after the U.S. FDA issued its Fast Track designation for its lead asset GLSI-100 to treat a subset of breast cancer patients. Specifically, the FDA has granted Fast Track status for ...